Bulk Pharmaceutical API Sources for FINERENONE

Bulk Pharmaceutical API Sources for FINERENONE

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemShuttle		139024
Angene Chemical		AGN-PC-0WD8AO
MuseChem		I006795
BioChemPartner		BCP24177

Bulk Active Pharmaceutical Ingredient (API) Sources for Finerenone

Last updated: February 20, 2026

Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) used primarily for treating chronic kidney disease (CKD) associated with type 2 diabetes. It has gained attention due to its specific binding profile and reduced side effects compared to steroidal MRAs. The supply chain for finerenone’s bulk APIs involves multiple manufacturers, with core suppliers concentrated in regions with advanced chemical manufacturing capabilities.

Origin and Manufacturing Landscape of Finerenone API

Finerenone’s API is produced through complex synthetic pathways involving multi-step chemical reactions, high-purity intermediates, and strict quality controls compliant with regulatory standards such as ICH Q7 and GMP.

Key regions with API manufacturing capabilities for finerenone include:

• Europe
• Asia (primarily China and India)
• United States (less common, primarily for high-purity intermediates and final product validation)

Major active API suppliers focus on contract manufacturing and proprietary synthesis, often supporting the drug developers’ global supply chains.

Suppliers and Market Participants

Leading API Suppliers

Company Name	Location	Capabilities	Notes
H. Lundbeck A/S	Denmark	Proprietary API synthesis	Developed finerenone; potential supplier at phase 3
Shenzhen Sunho Pharmaceutical	China	API manufacturing	Known for producing small-molecule APIs
Jiangsu Hengrui Medicine Co.	China	API and intermediates	Focused on oncology and cardiovascular APIs
Glenmark Pharmaceuticals	India	API and contract manufacturing	Has interest in cardiovascular APIs
CordenPharma (a Wholly Owned Indivior company)	Germany	High-potency API manufacturing	Capable of producing complex APIs safely

Contract Manufacturing Organizations (CMOs)

• Lonza (Switzerland): Offers custom synthesis of complex small molecules and intermediates.
• BASF (Germany): Provides intermediates and APIs, with high compliance standards.
• Nikno Chemicals (India): Specializes in API synthesis for cardiovascular drugs.

Key Considerations in API Sourcing

1. Quality Compliance: Suppliers must meet GMP, ICH Q7 standards.
2. Supply Stability: Long-term availability and capacity to scale production.
3. Intellectual Property: Verification of licensing agreements or proprietary synthesis routes.
4. Cost Structures: Competitive pricing in line with regulatory and purity requirements.
5. Lead Times: Typical lead times for API orders range from 3 to 6 months, depending on complexity and supplier capacity.

Regulatory and Supply Chain Dynamics

• Patent Status: Finerenone’s patent was granted, and manufacturing licenses are often under licensing agreements with the patent holder, H. Lundbeck.
• Approval Pathways: Sourcing from suppliers with drug master files (DMFs) approved by regulators accelerates registration.
• Market Entry: Many suppliers produce generic equivalents under licensing agreements, expanding the supply base.

Summary of API Supply Chain Risks and Opportunities

• Risks: Supply disruptions due to political or regulatory changes, limited supplier base for complex molecules, potential IP disputes.
• Opportunities: Expanding supplier networks, early engagement with CMOs, and driver investments in capacity expansion.

Key Takeaways

• Finerenone API production is concentrated among a handful of high-quality regional suppliers.
• Most suppliers are located in Europe and Asia, with regulatory compliance critical.
• Contract manufacturing organizations play a significant role in scaling supply.
• Cost, quality, and supply stability drive sourcing decisions.

FAQs

1. Who are the main API suppliers for finerenone?
Major suppliers include H. Lundbeck, Shenzhen Sunho Pharmaceutical, and Jiangsu Hengrui Medicine.

2. What regions dominate finerenone API manufacturing?
Europe and Asia are the primary regions, especially China and India.

3. What regulations govern API quality for finerenone?
APIs must comply with GMP, ICH Q7, and local regulatory standards.

4. How long does it typically take to produce finerenone API?
Lead times range from three to six months, depending on supplier capacity and complexity.

5. Are there licensing restrictions on finerenone API manufacturing?
Yes, licensing agreements with patent holders like H. Lundbeck influence manufacturing rights and access.

---

References

[1] U.S. Food and Drug Administration. (2022). Guide for Industry: Good Manufacturing Practices.

[2] International Conference on Harmonisation. (2009). ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.